MPH MD - NRX Pharmaceuticals Chief CoFounder

NRX Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (1.4566) % which means that it has lost $1.4566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8261) %, meaning that it created substantial loss on money invested by shareholders. NRX Pharmaceuticals' management efficiency ratios could be used to measure how well NRX Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NRX Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 03/18/2025, Return On Equity is likely to grow to 1.14, though Return On Tangible Assets are likely to grow to (6.54). As of 03/18/2025, Total Current Liabilities is likely to drop to about 14.9 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 6.3 M

Similar Executives

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded in 2015 and is based in Wilmington, Delaware. Nrx Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. NRX Pharmaceuticals (NRXP) is traded on NASDAQ Exchange in USA. It is located in 1201 Orange Street, Wilmington, DE, United States, 19801 and employs 14 people. NRX Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

NRX Pharmaceuticals Leadership Team

NRX Stock Performance Indicators

Additional Tools for NRX Stock Analysis